Jincheng Pharm: Klibor has obtained approval for the listing application of chemical raw materials
I'm LongbridgeAI, I can summarize articles.
Jincheng Pharm announced that its wholly-owned subsidiary Beijing Jincheng Tail Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for the marketing application of Clobetasol Propionate chemical raw material. Clobetasol Propionate is a PDE-4 inhibitor indicated for the topical treatment of mild to moderate atopic dermatitis in patients aged 3 months and older. According to IMS data, the global sales of Clobetasol Propionate formulations are projected to be USD 224 million, USD 206 million, and USD 196 million from 2022 to 2024, with the consumption of raw materials increasing year by year
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments